← Back to patent-cliff list
SAL-0120
Tier C — Watch / tradeSAL-0120
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ETAR
Indications (approved)：Hypertension, Chronic renal impairment, Essential hypertension, 免疫球蛋白a肾病
Regional status
US
-
EU
-
China
Phase III
2024-10-29
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SAL-0120?
Approved indications include: Hypertension, Chronic renal impairment, Essential hypertension, 免疫球蛋白a肾病.
When does the SAL-0120 patent expire?
No public expiry year is available for SAL-0120 yet; this page updates once verified.
How do I get a quote for SAL-0120 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01